PortfoliosLab logoPortfoliosLab logo
MCY vs. BMY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MCY vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Mercury General Corporation (MCY) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MCY achieves a 3.22% return, which is significantly lower than BMY's 3.70% return. Over the past 10 years, MCY has outperformed BMY with an annualized return of 10.61%, while BMY has yielded a comparatively lower 0.60% annualized return.


MCY

1D
-1.73%
1M
1.31%
YTD
3.22%
6M
7.65%
1Y
50.53%
3Y*
50.99%
5Y*
13.03%
10Y*
10.61%

BMY

1D
0.48%
1M
-4.64%
YTD
3.70%
6M
9.77%
1Y
19.47%
3Y*
-1.44%
5Y*
0.60%
10Y*
0.60%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MCY vs. BMY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
MCY
Mercury General Corporation
3.22%44.10%82.26%13.59%-32.61%6.18%13.44%-1.23%1.68%-7.23%
BMY
Bristol-Myers Squibb Company
3.70%0.11%15.81%-26.14%18.98%2.88%0.41%27.74%-12.90%7.71%

Correlation

The correlation between MCY and BMY is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.28

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (10Y)
Calculated over the trailing 10-year period

0.24

Correlation (All Time)
Calculated using the full available price history since Mar 27, 1990

0.23

Fundamentals

Market Cap

MCY:

$5.36B

BMY:

$111.82B

EPS

MCY:

$11.73

BMY:

$3.57

PE Ratio

MCY:

8.25

BMY:

15.35

PEG Ratio

MCY:

0.11

BMY:

0.88

PS Ratio

MCY:

1.16

BMY:

2.30

PB Ratio

MCY:

542.73

BMY:

5.57

Total Revenue (TTM)

MCY:

$4.60B

BMY:

$48.48B

Gross Profit (TTM)

MCY:

$2.09B

BMY:

$33.33B

EBITDA (TTM)

MCY:

$885.13M

BMY:

$13.34B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MCY vs. BMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MCY
MCY Risk / Return Rank: 8585
Overall Rank
MCY Sharpe Ratio Rank: 8787
Sharpe Ratio Rank
MCY Sortino Ratio Rank: 8383
Sortino Ratio Rank
MCY Omega Ratio Rank: 8181
Omega Ratio Rank
MCY Calmar Ratio Rank: 8787
Calmar Ratio Rank
MCY Martin Ratio Rank: 8888
Martin Ratio Rank

BMY
BMY Risk / Return Rank: 6363
Overall Rank
BMY Sharpe Ratio Rank: 6464
Sharpe Ratio Rank
BMY Sortino Ratio Rank: 5959
Sortino Ratio Rank
BMY Omega Ratio Rank: 5656
Omega Ratio Rank
BMY Calmar Ratio Rank: 6767
Calmar Ratio Rank
BMY Martin Ratio Rank: 6767
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MCY vs. BMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Mercury General Corporation (MCY) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


MCYBMYDifference
Sharpe ratioReturn per unit of total volatility

+1.22

Sortino ratioReturn per unit of downside risk

+1.29

Omega ratioGain probability vs. loss probability

1.32

1.15

+0.17

Calmar ratioReturn relative to maximum drawdown

3.95

1.43

+2.52

Martin ratioReturn relative to average drawdown

10.85

3.16

+7.69

MCY vs. BMY - Sharpe Ratio Comparison

The current MCY Sharpe Ratio is 1.96, which is higher than the BMY Sharpe Ratio of 0.74. The chart below compares the historical Sharpe Ratios of MCY and BMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


MCYBMYDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.96

0.74

+1.22

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.38

0.03

+0.36

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.33

0.02

+0.31

Sharpe Ratio (All Time)

Calculated using the full available price history

0.45

0.34

+0.11

Drawdowns

MCY vs. BMY - Drawdown Comparison

The maximum MCY drawdown since its inception was -68.83%, roughly equal to the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for MCY and BMY.


Loading charts...

Drawdown Indicators


MCYBMYDifference

Max Drawdown

Largest peak-to-trough decline

-68.83%

-72.03%

+3.20%

Max Drawdown (1Y)

Largest decline over 1 year

-12.87%

-13.68%

+0.81%

Max Drawdown (3Y)

Largest decline over 3 years

-39.99%

-36.85%

-3.14%

Max Drawdown (5Y)

Largest decline over 5 years

-54.32%

-47.67%

-6.65%

Max Drawdown (10Y)

Largest decline over 10 years

-55.28%

-47.67%

-7.61%

Current Drawdown

Current decline from peak

-6.01%

-21.26%

+15.25%

Average Drawdown

Average peak-to-trough decline

-18.77%

-22.38%

+3.61%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.67%

6.17%

-1.50%

Volatility

MCY vs. BMY - Volatility Comparison

Mercury General Corporation (MCY) has a higher volatility of 7.73% compared to Bristol-Myers Squibb Company (BMY) at 6.06%. This indicates that MCY's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MCYBMYDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.73%

6.06%

+1.67%

Volatility (6M)

Calculated over the trailing 6-month period

19.23%

18.48%

+0.75%

Volatility (1Y)

Calculated over the trailing 1-year period

25.92%

26.64%

-0.72%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

34.13%

23.98%

+10.15%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

31.85%

25.24%

+6.61%

Dividends

MCY vs. BMY - Dividend Comparison

MCY's dividend yield for the trailing twelve months is around 1.31%, less than BMY's 4.57% yield.


PositionTTM20252024202320222021202020192018201720162015
BMY
Bristol-Myers Squibb Company
4.57%4.60%4.24%4.44%3.00%2.36%3.69%2.55%3.08%2.55%1.95%2.17%
MCY
Mercury General Corporation
1.31%1.35%1.91%3.40%5.57%4.77%4.83%5.16%4.84%4.66%4.12%5.31%

Financials

MCY vs. BMY - Financials Comparison

This section allows you to compare key financial metrics between Mercury General Corporation and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B12.00B20222023202420252026
1.54M
11.49B
(MCY) Total Revenue
(BMY) Total Revenue
Values in USD except per share items

MCY vs. BMY - Profitability Comparison

The chart below illustrates the profitability comparison between Mercury General Corporation and Bristol-Myers Squibb Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-20.0%0.0%20.0%40.0%60.0%80.0%202220232024202520260
70.2%
Portfolio components
MCY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Mercury General Corporation reported a gross profit of 0.00 and revenue of 1.54M. Therefore, the gross margin over that period was 0.0%.

BMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.

MCY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Mercury General Corporation reported an operating income of 0.00 and revenue of 1.54M, resulting in an operating margin of 0.0%.

BMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.

MCY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Mercury General Corporation reported a net income of 190.42K and revenue of 1.54M, resulting in a net margin of 12.4%.

BMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.


Frequently Asked Questions


MCY and BMY have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MCY has higher volatility (7.73%) compared to BMY (6.06%). In terms of maximum drawdown, MCY dropped -68.83% vs BMY's -72.03%.

MCY currently has the higher Sharpe Ratio (1.96 vs 0.74), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MCY and BMY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer